Pulmonary Langerhans Cell Histiocytosis (PLCH) Clinical Trials

Pulmonary Langerhans Cell Histiocytosis results from clonal proliferation of Langerhans cells (a type of dendritic cell) in the lungs, causing inflammation and progressive parenchymal destruction. Recent molecular studies have identified somatic mutations in BRAF and MAPK pathway genes in many PLCH cases, suggesting this is a clonal neoplastic process rather than purely inflammatory. The accumulation of Langerhans cells leads to nodular infiltration, ground-glass opacities, and characteristic cyst formation with upper and middle lobe predominance.

The most common symptoms of Pulmonary Langerhans Cell Histiocytosis include Progressive dyspnea on exertion, Chronic cough, often dry initially, Chest pain or discomfort, Fatigue and reduced exercise tolerance, Spontaneous pneumothorax from lung cyst rupture, among others. Approximately 0.07 to 0.4 per 100,000 person-years; rare form of interstitial lung disease. Symptoms can range from mild to severe and may vary between individuals.

Trial Friend lists all active clinical trials for Pulmonary Langerhans Cell Histiocytosis from ClinicalTrials.gov, with eligibility criteria translated into plain English. Patients can filter by trial phase and recruitment status, search by location, and use the Match Me tool to score trials against their profile. Research in Pulmonary Langerhans Cell Histiocytosis is increasingly focused on understanding and treating the underlying molecular drivers of disease. Trials evaluate both conventional approaches including corticosteroids and cladribine alongside newer targeted therapies.

As of October 21, 2026, no current FDA drug label names Pulmonary Langerhans Cell Histiocytosis as a condition the drug treats.

Pulmonary Langerhans Cell Histiocytosis arises from acquired (somatic) genetic changes in the affected cells, commonly involving BRAF, rather than from an inherited variant. Cigarette smoking is the main trigger, but activating MAP-kinase pathway changes were found in 86% of adult lesions in a 2020 French study, most often BRAF V600E, followed by BRAF deletions and MAP2K1 variants; nothing is inherited. Approximately 0.07 to 0.4 per 100,000 person-years; rare form of interstitial lung disease.

For Pulmonary Langerhans Cell Histiocytosis the genetic testing that matters is usually of the tumor or affected blood cells rather than inherited DNA, looking for BRAF. Cigarette smoking is the main trigger, but activating MAP-kinase pathway changes were found in 86% of adult lesions in a 2020 French study, most often BRAF V600E, followed by BRAF deletions and MAP2K1 variants; nothing is inherited.

Those results guide treatment choice and are often the entry requirement for targeted-therapy trials, so ask whether the biopsy was sent for molecular testing and request the report. The Genetic Testing section of this page lists laboratories in the NIH Genetic Testing Registry.

Eligibility for Pulmonary Langerhans Cell Histiocytosis clinical trials depends on factors like age, diagnosis, treatment history, and overall health. Each trial sets its own inclusion and exclusion criteria. Trial Friend translates these requirements from medical language into plain English so patients can review them more easily. The Match Me tool can score your profile against active trials to help identify studies that may be a fit.

Participating in a Pulmonary Langerhans Cell Histiocytosis clinical trial typically involves scheduled visits, medical tests, and close monitoring by a research team. Depending on the study phase, you may receive an investigational treatment, a placebo, or the current standard of care. Trials may last from a few weeks to several years. Study participation is voluntary, and you can withdraw at any time.